22 June 2016 : With this collaboration, OGD2 Pharma and GCLC will explore the potential of targeting NK-cells to the OAcGD2 antigen using humanized antibody and chimeric antigen receptors (CAR) for fighting against solid tumors.
“Thanks to this collaboration OGD2 Pharma speeds-up the development of its anti-OAcGD2 CAR platform. We highly value Green Cross leadership in allogenic NK-cell therapy and their proven ability to develop and to market cell therapy products” said Jean-Marc Le Doussal, President at OGD2 Pharma. “OGD2 Pharma will continue building strategic partnerships with academic groups and private companies in other fields of cell therapies.” he added.
Press release: OGD2 GCLC PR 2016 06 22 release